Search
Mild Cognitive Impairment Clinical Trials
A listing of 124 Mild Cognitive Impairment clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 124
There are currently 124 active clinical trials seeking participants for Mild Cognitive Impairment research studies. The states with the highest number of trials for Mild Cognitive Impairment participants are Florida, California, New York and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Wake Forest Alzheimer's Disease Clinical Core
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/25/2025
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
Recruiting
The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help determine whether diet interventions induce changes in cognitive function, cerebral blood flow, and levels of certain proteins and hormones in body fluids.
The study will include volunteers who have mild cognitive impairment, who will be randomly assigned to... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
07/25/2025
Locations: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Alzheimer Disease, Mild Cognitive Impairment
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
Recruiting
The objective of this study is to test the effects of caffeine on neurocognitive and clinical recovery after major surgery. Specifically, this trial tests the primary hypothesis that caffeine will reduce the incidence of postoperative delirium.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
07/22/2025
Locations: Michigan Medicine, Ann Arbor, Michigan
Conditions: Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Race-Based Stress and Cognitive Training for MCI
Recruiting
This a two phase project that aims to pilot a new adaptation (Phase 1) of Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT; an originally VA-based cognitive rehabilitation manualized intervention for older adults with MCI, with a focus on the impact of stress on cognitive functioning; that integrates components from the Race Based Stress and Empowerment (RBSE) group for an increased focus on race-based stress and discrimination for racial minority old... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/21/2025
Locations: Rosalind Franklin University of Medicine and Science, Chicago, Illinois
Conditions: Mild Cognitive Impairment
Voice Technology-Based Self-Management Intervention
Recruiting
This study aims to test a new technology-based program designed to help improve the ability to manage chronic conditions.
This program includes daily smart speaker use for managing different tasks and technology learning.
Proper self-management of chronic conditions is critical to the maintenance of health. Digital technologies offer substantial potential to enhance self-management behaviors. Voice-operated smart speakers hold promise due to their ability to provide functional, cognitive, and... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/18/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Mild Cognitive Impairment
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
Recruiting
CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/18/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
Everyday Memory Impairment in PD-related Cognitive Decline
Recruiting
The investigators will aim enroll participants into our study within 3-6 months after their parent study visit so the investigators can utilize some key data points (e.g. PD-MCI diagnosis, rs-fcMRI data) from that study. PD participants will participate in a single-blind RCT with two treatment arms: process training and strategy training (Fig 4). They will complete pre-training assessment (Pre), be randomized to treatment arm (1:1 ratio stratified by sex), and then complete 8 training sessions o... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/14/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Parkinson Disease, Mild Cognitive Impairment
Senicapoc in Alzheimer's Disease
Recruiting
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Co... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
07/14/2025
Locations: University of California, Davis Alzheimer's Disease Center, Sacramento, California +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
ALL
Ages:
Between 40 years and 64 years
Trial Updated:
07/11/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +22 locations
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/11/2025
Locations: JEM Research Institute, Atlantis, Florida +22 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
MCI Speech in Noise
Recruiting
The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how t... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/09/2025
Locations: Space Medicine Lab at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Mild Cognitive Impairment
ALIGN: Aligning Medications With What Matters Most (Demonstration)
Recruiting
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.
The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Community Physicians, Baltimore, Maryland
Conditions: Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
1 - 12 of 124